Overview

Effectiveness and Safety of Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Melasma and Facial Hyperpigmentation

Status:
Not yet recruiting

Trial end date:
2019-10-29

Target enrollment:

Participant gender:

Summary

Melasma and facial hyperpigmentation (dark spots) are common skin issues that can cause embarrassment and affect the quality of life in majority of people. We are conducting a research to study an effectiveness and safety of Isobutylamido-thiazolyl-resorcinol 0.2% in the treatment of melasma, freckles, lentigo and dark spots in comparison to vehicle intervention in 4, 8 and 12-week period. Our ultimate goal is to provide the best medical treatments to improve physical and mental health for the people who suffer from melasma and facial hyperpigmentation.

Phase:

Phase 3

Details

Lead Sponsor:

Institute of Dermatology, Thailand

Collaborator:

Beiersdorf (Thailand) Co., Ltd.